Need to Know: Why Coke, others, may be spared, as a $100 billion opportunity in weight loss drugs unfolds says JPMorgan

by | Oct 24, 2023 | Stock Market

Let’s hear it for retail investors, who don’t get enough credit for taking care of business. Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500’s
SPX
during the same period.

All that is largely thanks to love for tech biggies like Apple and Tesla, as savvy investors picked up on their importance. And who wouldn’t want to hop on the next big theme and be sitting on big gains in a decade or two. That brings us to our call of the day, from JPMorgan, which is flagging a “$100 billion plus opportunity” from emerging weight-loss drugs, or GLP-1s — glucagon-like peptide-1 gut hormones that can help control blood sugar levels and lower appetites. “We forecast U.S. sales for the GLP-1 category to exceed $100 billion in annual sales over time, split roughly 50/50 in diabetes and obesity. Our global market estimate is [more than] $140 billion by 2032,” said a team led by analyst Nicholas Rosato, whose estimates crush the $77 billion in sales by 2030 predicted by Morgan Stanley this summer. His team is bullish on U.S. and Europe picks Eli Lilly
LLY,
-1.37%
and Novo Nordisk
NVO,
+0.86%
NOVO.B,
-0.97%,
and they see plenty of upside ear …

Article Attribution | Read More at Article Source

$140 billion by 2032,” said a team led by analyst Nicholas Rosato, whose estimates crush the $77 billion in sales by 2030 predicted by Morgan Stanley this summer. His team is bullish on U.S. and Europe picks Eli Lilly
LLY,
-1.37%
and Novo Nordisk
NVO,
+0.86%
NOVO.B,
-0.97%,
and they see plenty of upside ear …nnDiscussion:nn” ai_name=”RocketNews AI: ” start_sentence=”Can I tell you more about this article?” text_input_placeholder=”Type ‘Yes'”]

Share This